Satoshi Wasamoto
Overview
Explore the profile of Satoshi Wasamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yanagisawa S, Wasamoto S, Takechi H, Hata Y
Intern Med
. 2021 Sep;
61(6):931-932.
PMID: 34483215
No abstract available.
12.
Yanagisawa S, Wasamoto S
Am J Respir Crit Care Med
. 2021 Apr;
204(6):e59-e60.
PMID: 33882265
No abstract available.
13.
Sekine A, Wasamoto S, Hagiwara E, Yamakawa H, Ikeda S, Okabayashi H, et al.
Respir Investig
. 2020 Nov;
59(2):247-251.
PMID: 33189601
Background: Interstitial lung disease (ILD) patients commonly become obese or overweight due to deteriorated daily living activities and the adverse effects of prednisolone. This study aimed to clarify the effect...
14.
Imai H, Minemura H, Kishikawa T, Yamada Y, Suzuki K, Umeda Y, et al.
Thorac Cancer
. 2020 Aug;
11(10):2867-2876.
PMID: 32844570
Background: S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly...
15.
Yamaguchi O, Imai H, Minemura H, Suzuki K, Wasamoto S, Umeda Y, et al.
Cancer Chemother Pharmacol
. 2020 Mar;
85(4):761-771.
PMID: 32193618
Purpose: Immune checkpoint inhibitors (ICIs) are an effective subsequent-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, it remains unclear whether the efficacy and safety of subsequent-line...
16.
Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, et al.
J Cancer Res Clin Oncol
. 2019 Dec;
146(2):457-466.
PMID: 31853661
Purpose: Pembrolizumab is an effective front-line treatment for advanced non-small cell lung cancer (NSCLC) in patients expressing high levels of programmed death-ligand 1 (PD-L1). However, it is unclear whether first-line...
17.
Yanagisawa S, Wasamoto S, Endoh H
Intern Med
. 2019 Jul;
58(23):3487-3488.
PMID: 31327841
No abstract available.